Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Seven sneaky clauses in estate agent contracts that can cost you dear
Village Officials Help Residents Resolve Marital, Family Disputes
Strengthening Protection of Children's Rights, Interests
Women Account for 42.9 Percent of Senior Professionals in Tibet
‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad
Organizations Aim for Better Protection of Women with Revised Law
Platform Helps Promote Family Harmony
China Promulgates Policies to Support Childbirth
Association Promotes Development of Scientific, Technological Women Workers
Jon Wysocki dead at 53: Staind drummer passes away
Court, Federation Publicize Top Cases Involving Protection of Minors' Rights